NCT07083362

Safety, Tolerability and Pharmacokinetic Study of HRS-8829

Safety, Tolerability and Pharmacokinetic Studies of Single and Multiple Administrations of HRS-8829 in Healthy Subjects

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into two parts: single-dose dose-escalation (SAD) and multiple-dose dose-escalation (MAD)

Conditions

• Acute Ischemia Stroke

Interventions

Type	Name	Description
DRUG	HRS-8829;Placebo	Subject will receive HRS-8829 at dose level 1. Subject will receive placebo at dose level 1.
DRUG	HRS-8829;Placebo	Subject will receive HRS-8829 at dose level 2. Subject will receive placebo at dose level 2.
DRUG	HRS-8829;Placebo	Subject will receive HRS-8829 at dose level 3. Subject will receive placebo at dose level 3.
DRUG	HRS-8829;Placebo	Subject will receive HRS-8829 at dose level 4. Subject will receive placebo at dose level 4.

Timeline

• Start date: 2025-07-01
• Primary completion: 2025-10-01
• Completion: 2025-11-01
• First posted: 2025-07-24
• Last updated: 2025-07-24

Locations

1 site across 1 country: China